alexa
Reach Us +44-1522-440391
Editor - Muhammad Bilal Abid | University of Bristol Cancer Inst | 23979
ISSN: 2165-7831

Journal of Blood & Lymph
Open Access

OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)
All submissions of the EM system will be redirected to Online Manuscript Submission System. Authors are requested to submit articles directly to Online Manuscript Submission System of respective journal.
Relevant Topics

Muhammad Bilal Abid

Muhammad Bilal Abid
Muhammad Bilal Abid University of Bristol Hospitals NHS Trust, United Kingdom

Biography

Dr. M. Bilal Abid graduated from the Aga Khan University School of Medicine Pakistan, completed USMLE examinations and internship from Penn State University Hershey Medical Center in Hershey Pennsylvania. He then moved to Singapore and completed internal medicine residency at the National University of Singapore (NUS) and then worked in the division of hematology/oncology and stem cell transplantation at the National University Cancer Institute of Singapore (NCIS). He is an avid clinical researcher and continues to publish research articles related to leukemia, lymphoma, myeloma, transplantation and infectious diseases. Dr. Abid also serves on the editorial board of several international journals and mentors students interested in clinical and translational research. He is currently a hematologist at the University of Bristol Cancer Institute in Bristol UK. In his spare time, Dr. Abid enjoys playing basketball and spending time with family and friends.

Research Interest

Leukemia, Lymphoma, Multiple Myeloma and Stem Cell Transplantation.

Leave Your Message 24x7
Top